A metabolic constraint in the kynurenine pathway drives mucosal inflammation in IBD - Welz, Lina; Harris, Danielle MM; Kim, Na-Mi; Alsaadi, Abrar I; Wu, Qicong; Oumari, Mhmd; Taubenheim, Jan; Volk, Valery; Credido, Graziella; Koncina, Eric; Mukherjee, Pranab K; Tran, Florian; et al. (medRxiv, 2024)
Inflammatory bowel disease (IBD) is associated with perturbed metabolism of the essential amino acid tryptophan (Trp). Whether increased degradation of Trp directly fuels mucosal inflammation or acts as a compensatory attempt to restore cellular energy levels via de-novo nicotinamide adenine dinucleotide (NAD+) synthesis is not understood. Employing a systems medicine approach on longitudinal IBD therapy intervention cohorts and targeted screening in preclinical IBD models, we discover that steady increases in Trp levels upon therapy success coincide with a rewiring of metabolic processes within the kynurenine pathway (KP). In detail, we identify that Trp catabolism in IBD is metabolically constrained at the level of quinolinate phosphorybosyltransferase (QPRT), leading to accumulation of quinolinic acid (Quin) and a decrease of NAD+. We further demonstrate that Trp degradation along the KP occurs locally in the inflamed intestinal mucosa and critically depends on janus kinase / signal transducers and activators of transcription (JAK/STAT) signalling. Subsequently, knockdown of QPRT in-vitro induces NAD+ depletion and a pro-inflammatory state, which can largely be rescued by bypassing QPRT via other NAD+ precursors. We hence propose a model of impaired de-novo NAD+ synthesis from Trp in IBD. These findings point towards the replenishment of NAD+ precursors as a novel therapeutic pathway in IBD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the BMBF iTREAT project (P.R., C.K.), DFG Cluster of excellence (ExC2167) Precision medicine in chronic inflammation RTF III, RTF-VIII and TI-1, the DFG CRC 1182 C2 (P.R.), the EU project miGut-Health (P.R.), the EKFS research grant #2019_A09 and EKFS Clinician Scientist Professorship (K.A., 2020_EKCS.11), the BMBF (eMED Juniorverbund Try-IBD 01ZX1915A, 01ZX2215, K.A., D.H.), the DFG RU5042 (P.R., K.A., C.K.), the Joachim Herz Stiftung (K.A.), NIH Grant T32GM108563 (A.I.A.), the Howard Hughes Medical Institute Hanna H. Gray Fellows Program Faculty Phase (Grant# GT15655, M.R.M), the Burroughs Welcome Fund PDEP Transition to Faculty (Grant# 1022604, M.R.M), the ECCO Multiyear Research Grant 2021 (K.A., B.V). and the Clinical Research Fund (KOOR) at the University Hospitals Leuven and the Research Council at the KU Leuven (B.V.). This project has furthermore received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853995 (ImmUniverse). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical studies conducted at the University Hospital Schleswig-Holstein, Campus Kiel, were approved by the ethics committee of the Christian Albrecht University of Kiel (D 490/20, D 489/20, A 124/14 and AZ 156/03-2/13) in accordance with the Declaration of Helsinki and all enrolled subjects provided written informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors3OHAnth3-Hydroxyanthranilic acid3OHKyn3-Hydroxy-kynurenine5OHTrp5-Hydroxy-tryptophanAADATadenosine deaminase acting on tRNAAnthAnthranilic acidEpaEpacadostatFilgoFilgotinibHIAA5-Hydroxy indoleacetic acidIDO1/2Indoleamine 2,3-dioxygenase extonehalfIFNγInterferon gammaILInterleukinIPAIndole-3-propionic acidJAK/STATJanus kinase / signal transducers and activators of transcriptionKPKynurenine pathwayKMOKynurenine-3-monooxygenaseKynKynurenineKynaKynurenic acidKYNUKynureninaseLPSLipopolysaccharidesNANicotinic acidNAD+Nicotinamide adenine dinucleotideNAMNicotinamideNAMNNicotinic acid mononucleotideNAPRTNicotinic acid phosphoribosyltransferaseNeoptNeopterinNMNAT3Nicotinamide nucleotide adenylyltransferase 3NRNicotinamide ribosidePicoPicolinic acidQPRTQuinolinate phosphorybosyltransferaseQuinQuinolinic acidSeroSerotoninTDOTryptophan-2,3-dioxygenaseTNFαTumor necrosis factor alphaTofaTofacitinibTrpTryptophanUpaUpadacitinibXanthXanthurenic acid